PUBLICATION ABSTRACT

BARRICAID

The Disability Cascade: A Preventable Consequence Of The Loss Of Disc Height Following Lumbar Microdiscectomy

Cureus: DOI: 10.7759/cureus.5169 https://doi.org/10.7759/cureus.5169 A Kursumovic, JM Muir, J Ammerman, R Bostelmann

Abstract

Lumbar discectomy is a mainstay surgical treatment for herniation of the lumbar discs and is effective at treating radicular symptomology. Despite the overall success of the procedure; the potential for reherniation and reoperation is significant. To avoid this potential recurrence, surgeons often perform discectomy more aggressively, removing a larger volume of nuclear material in the hopes of minimizing the likelihood of reherniation. This approach, while beneficial in minimizing the chance of reherniation, is associated with a volumetric reduction of the nucleus within the disc space, making the disc more prone to collapse and thus inducing a significant post-operative loss of disc height. While potentially minor in isolation, the loss of disc height, in fact, impacts several aspects of overall patient well-being. We hypothesize that the loss of disc height following discectomy causes an increase in pain and subsequent disability, the combination of which ultimately impacts socioeconomic factors affecting both the patient and the healthcare system as a whole. In this report, we outline the evidence in support of this disability cascade and provide recommendations on methods for limiting its impact. Given the current focus on cost-effectiveness in healthcare decision-making, methods for limiting this potentially damaging sequence of events must be investigated.

This article contains off-label use information. Please use medical discretion when reviewing this article.

Barricaid is approved for the following indications for use:

Reducing the incidence of reherniation and reoperation in skeletally mature patients with radiculopathy (with or without back pain) attributed to a posterior or posterolateral herniation, and confirmed by history, physical examination and imaging studies which demonstrate neural compression using MRI to treat a large anular defect (between 4-6 mm tall and between 6-10 mm wide) following a primary discectomy procedure (excision of herniated intervertebral disc) at a single level between L4 and S1.

Financial disclosure:

One or more authors have received financial compensation from Intrinsic Therapeutics. Full financial disclosures can be found in the respective manuscript.

WARNING: This product has labeling limitations. See package insert for additional warnings, precautions and possible adverse effects.

CAUTION: USA law restricts this device to sale by or on the order of physician. All medical devices have associated risks. Please refer to the package insert and other labeling for a complete list of indications, contraindications, precautions and warnings (www.barricaid.com/us-en/instructions). For further information on Barricaid, contact your Intrinsic representative.



Intrinsic Therapeutics, Inc. 30 Commerce Way, Woburn, MA 01801 USA





